SCHEMBL24847490

SCHEMBL24847490

CCCC(=O)CCCCc1cc(OCC)ccc1C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 7/20 0.41
▸ TSHR P16473 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ HPGD P15428 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ CNR1 P21554 2/20 0.38
▸ MTNR1A P48039 1/20 0.38
▸ MTNR1B P49286 1/20 0.38
▸ SQSTM1 Q13501 1/20 0.38
▸ KEAP1 Q14145 1/20 0.38
▸ NFE2L2 Q16236 1/20 0.38
▸ CYP4F2 P78329 1/20 0.38
▸ CYP4A11 Q02928 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22526265 0.83 L3MBTL1 (0.43) CNR2TSHRKMT2ACNR1MTNR1A
SCHEMBL25123251 0.83 CNR2 (0.42) CNR2TSHRNPC1ALDH1A1MEN1
SCHEMBL26224372 0.78 TSHR (0.38) CNR2TSHRALDH1A1MEN1KMT2A
SCHEMBL22526269 0.78 FOS (0.40) CNR2TSHRALDH1A1MEN1KMT2A
SCHEMBL22527268 0.75 CNR2 (0.46) CNR2TSHRCNR1
SCHEMBL9159855 0.75 NQO1 (0.45) TSHRNPC1ALDH1A1MEN1KMT2A
SCHEMBL23189235 0.74 IAPP (0.39) ALDH1A1KDM4ECYP1A2SMN1; SMN2HSD17B10
SCHEMBL14183051 0.74 NQO1 (0.52) TSHRNPC1ALDH1A1MEN1KMT2A
SCHEMBL14583346 0.73 CNR2 (0.50) CNR2TSHRALDH1A1MEN1KMT2A
SCHEMBL24029703 0.72 FOS (0.41) CNR2NPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023278759-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 — — WO disclosed
Send feedback